159 related articles for article (PubMed ID: 35629160)
1. Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma.
Ma A; Biersack B; Goehringer N; Nitzsche B; Höpfner M
J Pers Med; 2022 May; 12(5):. PubMed ID: 35629160
[TBL] [Abstract][Full Text] [Related]
2. New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells.
Schaller E; Ma A; Gosch LC; Klefenz A; Schaller D; Goehringer N; Kaps L; Schuppan D; Volkamer A; Schobert R; Biersack B; Nitzsche B; Höpfner M
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668139
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors.
Goehringer N; Biersack B; Peng Y; Schobert R; Herling M; Ma A; Nitzsche B; Höpfner M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445133
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
5. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
6. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.
Kuo ZK; Lin MW; Lu IH; Yao HJ; Wu HC; Wang CC; Lin SH; Wu SY; Tong TS; Cheng YC; Yen JH; Ko CH; Chiou SJ; Pan IH; Tseng HW
BMC Complement Altern Med; 2016 Aug; 16():277. PubMed ID: 27502492
[TBL] [Abstract][Full Text] [Related]
8. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
9. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
10. Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer.
Bär SI; Dittmer A; Nitzsche B; Ter-Avetisyan G; Fähling M; Klefenz A; Kaps L; Biersack B; Schobert R; Höpfner M
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35485292
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog.
Liu H; Liang Y; Wang L; Tian L; Song R; Han T; Pan S; Liu L
PLoS One; 2012; 7(10):e48075. PubMed ID: 23118928
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
13. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
14. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
15. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
[TBL] [Abstract][Full Text] [Related]
16. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells.
Liao YJ; Bai HY; Li ZH; Zou J; Chen JW; Zheng F; Zhang JX; Mai SJ; Zeng MS; Sun HD; Pu JX; Xie D
Cell Death Dis; 2014 Mar; 5(3):e1137. PubMed ID: 24651440
[TBL] [Abstract][Full Text] [Related]
17. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
18. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
19. 5,6-Dihydroxy-3,7,4'-trimethoxyflavonol induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma cells.
Zhao XX; Chang JJ; Wang QL; Lu R; Li LJ; Sun X; Xie WD; Li X
J Asian Nat Prod Res; 2016 Nov; 18(11):1079-90. PubMed ID: 27314303
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
